Galvanize Therapeutics Announces Promising Data on the Aliya ™ Pulsed Electric Field (PEF) System in Early-Stage Non-Small Cell Lung Cancer
SAN DIEGO, Nov. 6, 2023 /PRNewswire/ -- Galvanize Therapeutics, Inc., a leader in developing pulsed electric field therapies, unveiled compelling data from the INCITE-ES clinical study at the recent Society for Immunotherapy for Cancer (SITC) conference. The study evaluated the ability of... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 6, 2023 Category: Pharmaceuticals Tags: TRI Source Type: news
Mirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation
SAN DIEGO and ZUG, Switzerland, Nov. 3, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, today announced the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) granted conditional marketing authorization... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 3, 2023 Category: Pharmaceuticals Tags: LIC Source Type: news
ACS Expands Lung Cancer Screening Eligibility ACS Expands Lung Cancer Screening Eligibility
The American Cancer Society recently updated its screening guidelines for lung cancer. Here ' s what ' s new.MDedge News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 3, 2023 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Experts Widen Criteria for Those Who Should Get Lung Cancer Screening
THURSDAY, Nov. 2, 2023 -- The American Cancer Society has expanded its recommendations for who should get lung cancer screening.
The updated guidance now says annual screening should start at a younger age and among those who smoke less, and it... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 2, 2023 Category: General Medicine Source Type: news
Johnson & Johnson Considers 3rd Bankruptcy for Talc Litigation
Johnson & Johnson may be filing for bankruptcy for a third time in an attempt to address its talc liabilities, this time under a different corporate structure. The pharmaceutical giant has twice failed at “Texas Two-Step” filings to resolve mass tort litigation against it.
Roughly 51,000 lawsuits filed against Johnson & Johnson claim the company’s talc-based products caused them to develop cancer. Johnson & Johnson’s two Chapter 11 bankruptcy filings through its subsidiary, LTL Management, were both denied by a New Jersey judge who found LTL did not qualify for bankruptcy protection becau...
Source: Asbestos and Mesothelioma News - November 2, 2023 Category: Environmental Health Authors: Fran Mannino Tags: Asbestos Exposure Legal Source Type: news
Millions more former smokers must be regularly screened for lung cancer, American Cancer Society says - do YOU need a check-up?
The American Cancer Society (ACS) extended its guideline for annual lung cancer screening to encompass older people who smoke or used to smoke, regardless of how long ago they stopped. (Source: the Mail online | Health)
Source: the Mail online | Health - November 2, 2023 Category: Consumer Health News Source Type: news
Lambert-Eaton Myasthenic Syndrome Underdiagnosed Alongside SCLC in the U.S.
(MedPage Today) -- PHOENIX -- While Lambert-Eaton myasthenic syndrome (LEMS) is known to be associated with small cell lung cancer (SCLC), researchers here suggested the autoimmune disorder is underdiagnosed in the U.S.
Using claims from a large... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 2, 2023 Category: Hematology Source Type: news
ACS: Millions More Should Get Lung Cancer Screening
(MedPage Today) -- The American Cancer Society (ACS) widened the pool of past and current smokers eligible for lung cancer screening in its new guideline recommendations, potentially opening the door to 5 million more U.S. adults.
Annual lung... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 2, 2023 Category: Hematology Source Type: news
NSCLC: Case for Combining Chemo and Osimertinib NSCLC: Case for Combining Chemo and Osimertinib
Mark G. Kris, MD, discusses perioperative therapy for locally advanced lung cancer and the potential implications for survival and cure.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 1, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news
New ACS lung cancer screening guidelines significantly increase eligibility
The American Cancer Society (ACS) has released an updated lung cancer screening (LCS) guideline, significantly increasing eligibility and bringing it into concordance with the U.S. Preventive Services Task Force's (USPSTF) recommendation released in 2021.
Published November 1 in CA: A Cancer Journal for Clinicians, the new guidance expands eligibility to include five million more U.S. adults compared to the previous 2013 recommendation, the ACS said. It urges yearly screening for lung cancer via low-dose CT (LDCT) exams for people aged 50 to 80 years old who are current or former smokers and have a 20-year or greater pac...
Source: AuntMinnie.com Headlines - November 1, 2023 Category: Radiology Authors: Kate Madden Yee Tags: Clinical News CT Thoracic Imaging Source Type: news
Millions more smokers should be screened for lung cancer, group says
The updated American Cancer Society guideline says former smokers should get annual CT scans long after they quit. (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - November 1, 2023 Category: Consumer Health News Authors: Laurie McGinley Source Type: news
Lunit touts studies to be presented at SITC meeting
Lunit noted that six studies featuring the use of its AI technology will be presented at the Society for Immunotherapy of Cancer (SITC) 2023 meeting being held November 1 to 5 in San Diego.The studies highlight the predictive value and analytical power of the company’s Lunit SCOPE suite in various types of cancer, such as non-small cell lung cancer (NSCLC) and triple-negative breast cancer, Lunit said.Lunit’s SCOPE IO software analyzes a patient’s cancer tissue slide image by observing the distribution of tumor-infiltrating lymphocytes, which fight cancer cells. Based on the spatial distribution pattern of tumor-infi...
Source: AuntMinnie.com Headlines - November 1, 2023 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Source Type: news
Protect Environmental and the American Lung Association Partner to Provide Professional No-Cost Radon Testing for Lung Cancer Awareness Month
More than 21,000 American lives are lost to radon-induced lung cancer every year, but exposure can be prevented. Together we can reverse this deadly trend. LOUISVILLE, Ky., Nov. 1, 2023 /PRNewswire-PRWeb/ -- November is Lung Cancer Awareness Month. Lung cancer is the deadliest type of... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 1, 2023 Category: Pharmaceuticals Tags: LIC Source Type: news
Lung cancer is more common among women than men ages 35 to 54
Among those 55 and older who have lung cancer, however, men still outnumber women, researchers found. (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - October 31, 2023 Category: Consumer Health News Authors: Linda Searing Source Type: news
The Exciting Potential of Antibody-Drug Conjugates in Lung Cancer
(MedPage Today) -- MedPage Today brought together three expert leaders for a virtual roundtable discussion on lung cancer: Moderator Roy Herbst, MD, PhD, was joined by Anne Chiang, MD, PhD, and So Yeon Kim, MD, all from the Yale Cancer Center in... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 31, 2023 Category: Hematology Source Type: news
